Obeldesivir Ebola access took a concrete step on 16 November 2026, when Gilead Sciences signed royalty-free licences with three generic drugmakers, Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories, so the experimental oral antiviral could be made and supplied in 127 mostly low- and lower-middle-income countries if a Phase 3 prevention trial in Congo’s Bundibugyo Ebola outbreak succeeds and regulators sign off. No one can use the generic supply yet: obeldesivir is not approved for any use anywhere, and the licences only activate once clinical data and authorisations support it.
The timing reflects how badly the outbreak is going. Africa CDC said this week that the epidemic, declared on 15 May, remains out of control six months on, with government data showing more than 11,200 infections and more than 5,500 deaths. There is still no licensed vaccine or treatment built for the Bundibugyo strain.
Key takeaways on obeldesivir Ebola licensing
- Gilead granted royalty-free voluntary licences for obeldesivir to Dr. Reddy’s (India), Eva Pharma (Egypt) and Ferozsons (Pakistan), covering 127 countries, including every African country that has reported cases in this outbreak.
- The licences are a readiness move. Generic makers can only supply the drug if trial data and regulatory approvals support its use.
- Obeldesivir is being tested as post-exposure prophylaxis (PEP) in EBO-PEP, a randomised, placebo-controlled Phase 3 field trial coordinated by the medical NGO ALIMA.
- Gilead is also widening its existing remdesivir licences to cover filovirus disease, pending results of the WHO-sponsored PARTNERS treatment trial.
- Gilead says it has donated more than 38,000 remdesivir vials to Congo, Uganda and Kenya for investigational use.
Why sign licences before the trial reads out?
In past outbreaks, the gap between a positive trial and pills reaching contacts in the field was measured in months. Technology transfer, building manufacturing lines, validating batches and filing with national regulators all take time. By signing now, Gilead and the three licensees can start that work in parallel with the trial, so that if EBO-PEP shows a benefit, generic product could move faster to ministries of health and humanitarian buyers. Gilead says technology transfer talks are under way and that it is discussing deals with further manufacturers.
The company described the move as preparing “for future access while clinical research is ongoing,” in the words of Jaime McCoy, vice president of Gilead Patient Solutions. The 127-country footprint mirrors the one Gilead used for remdesivir generics during COVID-19, a programme the company says reached more than 8.1 million patients in low- and middle-income countries.
What obeldesivir is, and what it is not
Obeldesivir is an oral nucleoside analogue related to remdesivir. Where remdesivir must be given by intravenous infusion, obeldesivir is a tablet, which matters enormously for prevention: a household contact or a nurse exposed on a ward can take a pill at home, without a drip, a cold chain or a clinic visit. Gilead has previously tested it in COVID-19 and RSV, and it has shown activity against several filoviruses in laboratory and animal studies.
What it lacks is human proof against Ebola. Animal data do not always translate, and the Bundibugyo species has had far less drug development than Zaire ebolavirus, the strain behind the 2014 to 2016 West Africa epidemic. The two antibody treatments approved for Ebola in the US target Zaire virus specifically, and Africa CDC has said no treatments or diagnostic tests were designed for Bundibugyo. That is why EBO-PEP is being run as a placebo-controlled study rather than a mass rollout.
The deal at a glance
| Item | Detail |
|---|---|
| Drug | Obeldesivir (oral, investigational) |
| Proposed use | Post-exposure prophylaxis of Bundibugyo virus disease |
| Licensees | Dr. Reddy’s Laboratories, Eva Pharma, Ferozsons Laboratories |
| Territory | 127 countries, mainly low- and lower-middle-income |
| Royalties | None (royalty-free voluntary licences) |
| Trigger to supply | Supportive trial data plus regulatory authorisation |
| Pivotal study | EBO-PEP, Phase 3, randomised, placebo-controlled, ongoing |
| Remdesivir | Licences expanded to filovirus disease; PARTNERS trial ongoing |
Where the outbreak stands
The Democratic Republic of the Congo outbreak began in Ituri province and has spread to eight provinces, making it the second-largest Ebola epidemic on record after West Africa’s. Africa CDC and aid groups point to insecurity in the east, large population movements, attacks on health workers, unpaid staff and shortages of fuel and surveillance teams. Two figures stand out: more than 80% of new cases are in people who were not on contact-tracing lists, and more than 65% of deaths happen in communities rather than treatment centres. Uganda has declared its spillover over, Kenya and Nigeria appear contained, and the Central African Republic and South Sudan are flagged as at risk. We tracked the earlier surge in our report on the Congo Ebola outbreak passing 11,000 cases.
Those numbers explain why a pill matters. When most new infections arise outside known contact chains, any preventive tool that is cheap, oral and easy to distribute could be deployed far more widely than infusions or ring vaccination with experimental candidates.
Market context
Outbreak antivirals sit at the edge of a large commercial category. According to Acumen Research and Consulting’s antiviral drugs market report, the global antiviral drugs market was projected to reach around US$74.7 billion by 2027, growing at a compound annual rate of about 3.7% from 2020. That report was last updated in March 2021, so treat the figures as indicative. The point for Ebola is that almost none of that revenue comes from filovirus drugs: products for outbreaks in poorer countries rarely pay back on their own, which is why royalty-free licensing, donations and public funding do most of the work.
Open questions
- Efficacy: No human data yet show obeldesivir prevents Bundibugyo disease. EBO-PEP’s timeline has not been published.
- Regulatory route: Each country, or a WHO prequalification or emergency listing, would need to authorise the drug before licensees can supply it.
- Price and volumes: Gilead did not disclose expected generic prices or how many courses each licensee could produce.
- High-income markets: The licences do not cover the US or Europe, where any supply would come from Gilead.
FAQ
Is obeldesivir approved for Ebola?
No. Obeldesivir is investigational and is not approved for Ebola or any other use in any country. It is being tested as prevention after exposure in the EBO-PEP Phase 3 trial.
Which companies will make generic obeldesivir?
Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories hold royalty-free licences for 127 countries. Gilead says more manufacturers may be added.
Is there a vaccine for Bundibugyo Ebola?
Not yet. The licensed Ebola vaccine targets the Zaire strain. Candidate vaccines for Bundibugyo are being studied in the Tumaini trial.
How is obeldesivir different from remdesivir?
Both are Gilead antivirals from the same chemical family, but obeldesivir is taken by mouth while remdesivir is infused. Remdesivir is being tested as an Ebola treatment in the PARTNERS trial; obeldesivir as prevention.
More coverage: US Ebola travel declaration and airline compliance and our pharmaceutical news section.
Sources: Gilead Sciences press release (16 Nov 2026); Africa CDC briefing via allAfrica. Market data: Acumen Research and Consulting. This article is for information only and is not medical or investment advice. Last updated 17 November 2026.

